


Micafungin sodium

Cat. No.:	HY-16321
CAS No.:	208538-73-2
Molecular Formula:	C ₅₆ H ₇₀ N ₉ NaO ₂₃ S
Molecular Weight:	1292.26
Target:	Fungal; Antibiotic
Pathway:	Anti-infection
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 32 mg/mL (24.76 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	0.7738 mL	3.8692 mL	7.7384 mL
	5 mM	0.1548 mL	0.7738 mL	1.5477 mL
	10 mM	0.0774 mL	0.3869 mL	0.7738 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (1.93 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (1.93 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (1.93 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Micafungin sodium (FK 463 sodium) is an antifungal agent which inhibits 1, 3-beta-D-glucan synthesis.

In Vitro

Micafungin (10 mg/mL) phenotypically decreases the formation of biofilm in most of the isolates. For all the genes tested, the levels of mRNA transcription are also decreased significantly in micafungin-treated samples cf. their untreated counterparts [1]. The combination of micafungin and KB425796-C is fungicidal and markedly reduces the number of CFU, in contrast to the fungistatic effects (no reduction in CFU) observed at all examined time points when each drug is used alone [2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Micafungin (1 mg/kg) significantly prolongs survival compared with mice administered saline. Animals given a combination of micafungin (0.1 mg/kg) and KB425796-C (32 mg/kg) show a trend towards prolonged survival in comparison with those treated with micafungin (0.1 mg/kg) alone. In the livers of micafungin-treated mice, the number of CFUs decreases, although the clearance effect is less than that found in the kidneys. Combination treatment with micafungin and KB425796-C results in a significant decrease in the number of CFUs compared with the treatment with micafungin alone at all examined doses. The clearance effect associated with KB425796-C in combination with micafungin is greater than that observed in AMPH-treated animals^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[2]

Each fungal isolate is incubated statically in yeast-maltose (YM) agar broth for 24 h at 30°C. *Cryptococcus neoformans* YC203 is grown in YM broth medium for 20 h at 30°C with shaking at 200 r.p.m. A cell suspension is prepared by washing the cultured cells once with sterile saline. *A. fumigatus* FP1305 is cultured on a potato dextrose agar (PDA) slant for 4 days, and spores are then harvested in sterile saline and collected by filtering through gauze. Antifungal activity against all isolates, with the exception of *C. neoformans*, is measured by the micro-broth dilution method in 96-well culture plates using RPMI 1640 medium supplemented with L-glutamine, but without sodium bicarbonate, and buffered to pH 7.0 with 0.165 m MOPS. For *C. neoformans*, yeast nitrogen base-glucose (YNBD) medium is used. For the assay, the test microorganism is inoculated into each well to yield 1×10^5 CFU/well, and the plates are then incubated for 20 h or 48 h at 37°C. Two end points are determined by microscopic observation: MEC, which is defined as a substantial reduction in fungal growth, and MIC, which is defined as a complete inhibition of growth.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[2]

Eight groups of ten female DBA/2 mice (7 weeks old) are intravenously injected with 2.0×10^6 *A. fumigatus* FP1305 spores. The test groups receive the following treatments: AMPH at 1 mg/kg of body weight/dose given intraperitoneally (i.p.) once daily (q.d.); micafungin at 0.1, 0.32 or 1 mg/kg of body weight/dose given subcutaneously (s.c.) (q.d.); micafungin given s.c. (0.1, 0.32 or 1 mg/kg q.d.) plus KB425796-C given i.p. (32 mg/kg) twice daily (b.i.d.); and saline (b.i.d.). Drugs are administered on days 1 and 2. Five mice in each group are killed 1 day after the completion of treatment. The livers and kidneys are aseptically removed, and each organ is then homogenized in 5 mL sterile saline. Serial 10-fold dilutions of the homogenates are plated on PDA and incubated for 48 h at 37°C, and the numbers of CFU per gram of tissue are then calculated. The survival rate of remaining five mice of each group are examined daily for 31 days after the challenge.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Clin Microbiol. 2017 Jun;55(6):1883-1893.
- J Antimicrob Chemother. 2020 Aug 1;75(8):2133-2140.
- mSphere. 2018 Nov 14;3(6). pii: e00547-18.
- Sci Rep. 2017 Feb 17;7:42886.
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Bazzi W, et al. The inhibitory effect of micafungin on biofilm formation by *Pseudomonas aeruginosa*. Biofouling. 2013 Jul 23.

[2]. Kai H, et al. Synergistic antifungal activity of KB425796-C in combination with micafungin against *Aspergillus fumigatus* and its efficacy in murine infection models. *J Antibiot (Tokyo)*. 2013 Jun 12.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA